Attached files

file filename
EX-10.13 - EX-10.13 - Rain Therapeutics Inc.d26404dex1013.htm
EX-4.1 - EX-4.1 - Rain Therapeutics Inc.d26404dex41.htm
EX-3.4 - EX-3.4 - Rain Therapeutics Inc.d26404dex34.htm
EX-3.2 - EX-3.2 - Rain Therapeutics Inc.d26404dex32.htm
EX-3.1 - EX-3.1 - Rain Therapeutics Inc.d26404dex31.htm
EX-1.1 - EX-1.1 - Rain Therapeutics Inc.d26404dex11.htm

As filed with the Securities and Exchange Commission on April 9, 2021

Registration No. 333-254998

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

AMENDMENT NO. 1

TO

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Rain Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   2834   82-1130967

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

8000 Jarvis Avenue, Suite 204

Newark, CA 94560

(510) 953-5559

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

Avanish Vellanki

Chief Executive Officer

Rain Therapeutics Inc.

8000 Jarvis Avenue, Suite 204

Newark, CA 94560

(510) 953-5559

(Name, address, including zip code, and telephone number, including

area code, of agent for service)

With copies to:

 

Ryan A. Murr
Branden C. Berns

Gibson, Dunn & Crutcher LLP

555 Mission Street

San Francisco, CA 94105-0921

(415) 393-8373

 

Brian J. Cuneo

Chris G. Geissinger

Latham & Watkins LLP

140 Scott Drive
Menlo Park, CA 94025

(650) 328-4600

Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of

Securities to be Registered

  Proposed Maximum
Aggregate Offering
Price(1)(2)
 

Amount of

Registration
Fee(3)

Common Stock, par value $0.001 per share

  $100,000,000   $10,910

 

 

(1)

Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended.

(2)

Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant. See the section titled “Underwriting.”

(3)

Paid in connection with the initial filing of the registration statement.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.

 

 

 


EXPLANATORY NOTE

This amendment is being filed solely to file certain exhibits to the Registration Statement.


PART II

INFORMATION NOT REQUIRED IN THE PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

The following table sets forth the various expenses, other than underwriting discounts and commissions, payable by the registrant in connection with the sale of common stock being registered. All of the amounts shown are estimated except the Securities and Exchange Commission registration fee and the FINRA filing fee.

 

     Amount
To Be
Paid
 

Securities and Exchange Commission registration fee

   $ 10,910  

FINRA filing fee

     *  

Nasdaq listing fee

     *  

Printing and engraving expenses

     *  

Legal fees and expenses

     *  

Accounting fees and expenses

     *  

Transfer agent and registrar fees

     *  

Miscellaneous fees and expenses

     *  
  

 

 

 

Total

   $             *  
  

 

 

 

 

*

To be completed by amendment.

Item 14. Indemnification of Directors and Officers.

The company is a Delaware corporation. Section 145(a) of the Delaware General Corporation Law (DGCL) provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.

 

II-1


Further subsections of DGCL Section 145 provide that:

 

  (1)

to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i) and (ii) of Section 145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys’ fees, actually and reasonably incurred by such person in connection therewith;

 

  (2)

the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise; and

 

  (3)

the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145.

As used in this Item 14, the term “proceeding” means any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of the company, and whether civil, criminal, administrative, investigative or otherwise.

Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the company under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act of 1933. The company’s organizational documents provide, in effect, that, to the fullest extent and under the circumstances permitted by Section 145 of the DGCL, the company will indemnify any and all of its officers and directors. Before the completion of this offering, the company intends to enter into indemnification agreements with its officers and directors. The company may, in its discretion, similarly indemnify its employees and agents. The company’s certificate of incorporation also relieves its directors from monetary damages to the company or its stockholders for breach of such director’s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section 102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i) for a breach of the duty of loyalty, (ii) for failure to act in good faith, (iii) for intentional misconduct or knowing violation of law, (iv) for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends or (v) for any transactions from which the director derived an improper personal benefit.

The company has purchased insurance policies that, within the limits and subject to the terms and conditions thereof, cover certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the company.

The form of Underwriting Agreement, to be entered into in connection with this offering and to be attached as Exhibit 1.1 hereto, provides for the indemnification by the underwriters of us and our officers and directors for certain liabilities, including liabilities arising under the Securities Act, and affords certain rights of contribution with respect thereto.

 

II-2


Item 15. Recent Sales of Unregistered Securities.

Since January 1, 2018, we have made the following sales of unregistered securities:

Issuances of Securities

Since January 1, 2018, we have made the following issuances of securities:

 

  1.

In April 2018, with a subsequent closing in December 2018, we issued and sold an aggregate of 3,731,208 shares of our Series A convertible preferred stock at a purchase price of $5.2632 per share to new and existing investors in exchange for aggregate consideration of approximately $19.4 million, composed of approximately $18.4 million in cash and $1.0 million pursuant to the conversion of our convertible promissory notes.

 

  2.

In October 2019, we issued and sold convertible promissory notes in an aggregate principal amount of $2.5 million to existing investors.

 

  3.

In June 2020, we issued and sold convertible promissory notes in an aggregate principal amount of $6.4 million to existing investors.

 

  4.

In September 2020, we issued and sold an aggregate of 12,542,198 shares of our Series B convertible preferred stock at a purchase price of $5.97 per share to new and existing investors in exchange for aggregate consideration of approximately $72.6 million, composed of approximately $63.5 million in cash and $9.1 million pursuant to the conversion of our convertible promissory notes.

The offers, sales and issuances of the securities listed in this Item 15 under this subheading “Issuances of Securities” were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule 501 of Regulation D promulgated under the Securities Act.

Grants of Stock Options

Since January 1, 2018, we have granted stock options to purchase an aggregate of              shares of our common stock at a weighted-average exercise price of $             per share to employees, directors and non-employee service providers.

None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The offers, sales and, issuances of the securities listed in this Item 15 under this subheading “Grants of Stock Options” were deemed to be exempt from registration under the Securities Act in reliance on Rule 701 promulgated under the Securities Act as offers and sales of securities pursuant to certain compensatory benefit plans and contracts relating to compensation in compliance with Rule 701 or Rule 175.

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits

 

Exhibit
Number

  

Description of Exhibit

1.1    Form of Underwriting Agreement.
3.1    Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect prior to the effectiveness of the registration statement.

 

II-3


Exhibit
Number

 

Description of Exhibit

3.2   Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect upon completion of this offering.
3.3**   Bylaws of the Registrant, as currently in effect.
3.4   Form of Amended and Restated Bylaws of the Registrant, to be in effect upon completion of this offering.
4.1   Form of Common Stock Certificate of the Registrant.
4.2**   Amended and Restated Investors’ Rights Agreement, dated September  2, 2020, by and among the Registrant and certain of its stockholders.
5.1*   Opinion of Gibson, Dunn & Crutcher LLP.
10.1**+   Form of Indemnification Agreement for directors and executive officers.
10.2**+   Amended and Restated 2018 Stock Option/Stock Issuance Plan and form of award agreement thereunder.
10.3*+   2021 Equity Incentive Plan.
10.4*+   2021 Employee Stock Purchase Plan.
10.5**+   Director Offer Letter, dated March 19, 2018, by and between the Registrant and Tran Nguyen.
10.6**+   Director Offer Letter, dated March 19, 2018, by and between the Registrant and Peter Radovich.
10.7**+   Employment Agreement, dated September 10, 2020, by and between the Registrant and Avanish Vellanki.
10.8**+   Employment Agreement, dated September 10, 2020, by and between the Registrant and Robert Doebele.
10.9**+   Offer Letter, dated October 1, 2020, by and between the Registrant and Nelson Cabatuan.
10.10**#   License Agreement, dated September 2, 2020, between the Registrant and Daiichi Sankyo Company, Limited.
10.11**#   Intellectual Property License Agreement, dated July 30, 2020, by and between the Registrant and Drexel University.
10.12**   Office Lease Agreement, dated September 25, 2018, between the Registrant and BSP Senita 8000 Jarvis, LLC, as amended.
10.13   Form of Exchange Agreement by and among the Registrant and the stockholders listed therein.
23.1**   Consent of Independent Registered Public Accounting Firm.
23.2*   Consent of Gibson, Dunn & Crutcher LLP (see Exhibit 5.1).
24.1**   Power of Attorney (see signature page hereto).

 

*

To be filed by amendment.

**

Previously filed.

+

Indicates management contract or compensatory plan.

#

Portions of the exhibit have been omitted for confidentiality purposes.

(b) No financial statement schedules are provided because the information called for is not required or is shown in the financial statements or the notes thereto.

 

II-4


Item 17. Undertakings.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned Registrant hereby undertakes that:

 

  (1)

For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance on Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be a part of this registration statement as of the time it was declared effective.

 

  (2)

For purposes of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-5


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newark, State of California, on this 9th day of April, 2021.

 

Rain Therapeutics Inc.
By:   /s/ Avanish Vellanki
  Avanish Vellanki
  Chairman and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates set forth opposite their names.

 

Signature

 

Title

 

Date

/s/ Avanish Vellanki

Avanish Vellanki

 

Chairman and Chief Executive Officer

(principal executive officer)

  April 9, 2021

/s/ Nelson Cabatuan

Nelson Cabatuan

 

Vice President of Finance and Administration

(principal financial and accounting officer)

  April 9, 2021

*

Franklin Berger

 

Director

  April 9, 2021

*

Aaron Davis

 

Director

  April 9, 2021

*

Gorjan Hrustanovic, PhD

 

Director

  April 9, 2021

*

Tran Nguyen

 

Director

  April 9, 2021

*

Peter Radovich

 

Director

  April 9, 2021

*

Stefani A. Wolff

 

Director

  April 9, 2021

 

*By:  

/s/ Avanish Vellanki

  Avanish Vellanki
  Attorney-in-fact

 

II-6